Prosecution Insights
Last updated: April 19, 2026
Application No. 18/282,974

MEDICAL COMPOSITION AND USE THEREOF

Final Rejection §103
Filed
Sep 19, 2023
Examiner
PALENIK, JEFFREY T
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
DKS CO., LTD.
OA Round
2 (Final)
54%
Grant Probability
Moderate
3-4
OA Rounds
3y 5m
To Grant
81%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
466 granted / 867 resolved
-6.3% vs TC avg
Strong +27% interview lift
Without
With
+26.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
48 currently pending
Career history
915
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
46.2%
+6.2% vs TC avg
§102
20.8%
-19.2% vs TC avg
§112
18.5%
-21.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 867 resolved cases

Office Action

§103
DETAILED ACTION Status of the Application Receipt is acknowledged of Applicants’ Amendments and Remarks, filed 22 January 2026, in the matter of Application N° 18/282,974. Said documents have been entered on the record. The Examiner further acknowledges the following: The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-14 are pending, where claims 1-3 and 6-14 remain withdrawn from consideration. No claims have been added or canceled. Claim 4 has been amended to recite that the resulting urethane resin retains the aliphatic group from the originating aliphatic isocyanate group. Support appears to be provided in the originally-filed disclosure. See e.g., ¶[0038]. No new matter has been added. Thus, claims 4 and 5 continue to represent all claims currently under consideration. Information Disclosure Statement One new Information Disclosure Statement (IDS) filed 15 December 2025 is acknowledged and has been considered. Withdrawn Rejections Rejection under 35 USC 102 Applicants’ amendment to claim 4 is persuasive in overcoming the previously raised anticipation rejection over Archambault et al. Said rejection is withdrawn. Rejection under 35 USC 102 Applicants’ amendment to claim 4 is persuasive in overcoming the previously raised anticipation rejection over Vakili et al. Said rejection is withdrawn. Rejection under 35 USC 102 Applicants’ amendment to claim 4 is persuasive in overcoming the previously raised anticipation rejection over Xu vet al. Said rejection is withdrawn. Maintained Rejections The following rejections are maintained from the previous Office Correspondence dated 27 October 2025 since the art which was previously cited continues to read on the amended and previously recited limitations. Claim Rejections - 35 USC §103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the Examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicants are advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the Examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 4 and 5 are rejected under 35 U.S.C. 103 as obvious over Xu et al. (Polymer; 2013; ISR reference) in view of Haruyuki (JP H07-53764(A); machine translation attached). The limitations of claims 4 and 5 are previously discussed. Xu discloses the production of polyethylene glycol-modified polyurethanes using PEG diglycidyl ether and PEG bis(amine) and that such attachments are accomplished through the reduction of H-bonded urea groups (see e.g., Abstract). Figure 1 discloses the reaction between polyhexamethylene carbonate diol (PCD) and 4,4’diphenylmethane diisocyanate (MDI) to produce an isocyanate-terminated prepolymer to which PEG is then grafted to the prepolymer. The Examiner notes that the limitation directed to the claimed isocyanate is that it is “derived from an aliphatic isocyanate.” The broadest reasonable interpretation of this limitation is that while the isocyanate of the claimed invention is “derived from” an aliphatic isocyanate, that the final derived form of the isocyanate may not necessarily be aliphatic. Based on this interpretation, the Examiner submits that Xu anticipates the claimed invention. To the extent that the instantly claimed subject matter is not anticipated by the descriptive matter of the reference, it would be so recognized by persons of ordinary skill in the chemical arts. Of particular note, Haruyuki discloses producing polyurethane urea through the addition of diisocyanate groups to either end of the compound (R1). See e.g., ¶[0006]-¶[0008]. The reference further defines such diisocyanates as including hexamethylene diisocyanate (HMDI). See e.g., Reference Example 2 at ¶[0022]. Thus, one would have more than a reasonable expectation of successfully creating the instantly claimed composition, particularly since the compositions taught in the reference, at the very least, represent obvious variations which very closely read on those compositions which are instantly claimed. That is, both 4,4’-diphenylmethane diisocyanate and hexamethylene diisocyanate are considered to be obvious variants of one another in view of their both possessing isocyanate groups on either end of their respective structures: PNG media_image1.png 200 400 media_image1.png Greyscale PNG media_image2.png 176 388 media_image2.png Greyscale MPEP §2144.06(II) states that “[i]n order to rely on equivalence as a rationale supporting an obviousness rejection, the equivalency must be recognized in the prior art, and cannot be based on Applicants’ disclosure or the mere fact that the components at issue are functional or mechanical equivalents.” In the instant case, both references disclose reacting a polycarbonate polyol compound with an isocyanate in order to produce a polyurethane urea compound. The overlapping disclosure leading to the reasonable expectation of success is that both isocyanate compounds are diisocyanates wherein the isocyanate groups flank the remainder of the structure. Therefore, the invention as a whole would also have been prima facie obvious to one of ordinary skill in the art, before the effective filing date of the instant invention, absent a clear showing of evidence to the contrary. Response to Arguments Applicants’ arguments with regard to the obviousness rejection of claims 4 and 5 under 35 USC 103(a) as being unpatentable over the combined teachings of Xu et al. and Haruyuki et al. have been fully considered, but they are not persuasive. Regarding the obviousness rejection, Applicants allege that Xu does not contain urea bonds. The Examiner disagrees. Figure 1 of Xu shows that the final polyurethane precursor contains urea bonds (circled): PNG media_image3.png 110 1078 media_image3.png Greyscale Thus, as discussed above, the Examiner respectfully maintains that applying the HMDI as disclosed by Haruyuki would present the ordinarily skilled artisan with a reasonable expectation of producing the instantly amended compound. Applicants’ arguments, for the above reasons, are found unpersuasive. Said rejection is therefore maintained. All claims under consideration remain rejected; no claims are allowed. Conclusion THIS ACTION IS MADE FINAL. Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Jeffrey T. Palenik whose telephone number is (571) 270-1966. The Examiner can normally be reached on 9:30 am - 7:00 pm; M-F (EST). If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Jeffrey T. Palenik/ Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Sep 19, 2023
Application Filed
Oct 23, 2025
Non-Final Rejection — §103
Jan 22, 2026
Response Filed
Feb 10, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599701
DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12594359
Antimicrobial bone cement
2y 5m to grant Granted Apr 07, 2026
Patent 12589069
OPHTHALMIC SUSPENSION COMPOSITION
2y 5m to grant Granted Mar 31, 2026
Patent 12577400
Novel Topical Skin Closure Compositions and Systems
2y 5m to grant Granted Mar 17, 2026
Patent 12576071
PHARMACEUTICAL COMPOSITIONS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
54%
Grant Probability
81%
With Interview (+26.9%)
3y 5m
Median Time to Grant
Moderate
PTA Risk
Based on 867 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month